Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Meiji Yasuda Asset Management Co Ltd.

Meiji Yasuda Asset Management Co Ltd. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 2,335 shares of the biopharmaceutical company’s stock after selling 35 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Regeneron Pharmaceuticals were worth $1,663,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Great Valley Advisor Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 5.0% during the third quarter. Great Valley Advisor Group Inc. now owns 442 shares of the biopharmaceutical company’s stock worth $465,000 after buying an additional 21 shares in the last quarter. Kingsview Wealth Management LLC raised its position in shares of Regeneron Pharmaceuticals by 2.6% in the third quarter. Kingsview Wealth Management LLC now owns 860 shares of the biopharmaceutical company’s stock worth $904,000 after acquiring an additional 22 shares during the period. Larson Financial Group LLC boosted its stake in shares of Regeneron Pharmaceuticals by 127.3% during the 3rd quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 28 shares in the last quarter. Independent Advisor Alliance acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $231,000. Finally, Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $39,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Wells Fargo & Company decreased their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Sanford C. Bernstein cut their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $640.14 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $629.02 and a 52-week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a market cap of $69.98 billion, a price-to-earnings ratio of 16.72, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The business has a fifty day moving average of $685.91 and a two-hundred day moving average of $805.04.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $11.86 EPS. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.